Dyadic International (DYAI) Share-based Compensation (2018 - 2026)
Dyadic International's (DYAI) quarterly Share-based Compensation came in at $5.6 million in Q1 2026, down 10.61% year-over-year from $6.3 million in Q1 2025, and up 2829.94% quarter-over-quarter from $192339.0 in Q4 2025.
Analysis
Dyadic International (DYAI) Share-based Compensation (2018 - 2026) Analysis & Trends
Dyadic International has disclosed Share-based Compensation across 9 years of filings, most recently posting $5.6 million for Q1 2026.
- In Q1 2026, Share-based Compensation fell 10.61% year-over-year to $5.6 million; the TTM figure through Mar 2026 stood at $5.6 million (down 10.61% YoY), while the FY2025 annual figure was $5.4 million, down 7.36% from the prior year.
- Share-based Compensation came in at $5.6 million for Q1 2026 at Dyadic International, up from $192339.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $6.3 million in Q1 2025 to a low of $192339.0 in Q4 2025.
- Average Share-based Compensation over 5 years is $4.4 million, with a median of $5.5 million recorded in 2023.
- The largest YoY upside for Share-based Compensation was 14.6% in 2022 against a maximum downside of 98.71% in 2022.
- Over 5 years, Share-based Compensation stood at $480734.0 in 2022, then tumbled by 38.04% to $297859.0 in 2023, then slipped by 7.74% to $274808.0 in 2024, then slumped by 30.01% to $192339.0 in 2025, then soared by 2829.94% to $5.6 million in 2026.
- Per Business Quant data, the three most recent Share-based Compensation figures were $5.6 million in Q1 2026, $192339.0 in Q4 2025, and $5.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.38 Bn | 192.39 Bn | 7.24 Bn | 247.00 Mn |
| 2 | Gilead Sciences | 180.22 Bn | 177.04 Bn | 6.22 Bn | 231.00 Mn |
| 3 | Vertex Pharmaceuticals | 131.28 Bn | 123.42 Bn | 2.84 Bn | 108.10 Mn |
| 4 | Regeneron Pharmaceuticals | 81.96 Bn | 73.97 Bn | 3.93 Bn | 243.00 Mn |
| 5 | Argenx Se | 60.49 Bn | 55.30 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.90 Bn | 48.76 Bn | 52.00 Mn | 120.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.41 Bn | 30.11 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 77.40 Mn |
| 9 | Roivant Sciences | 29.08 Bn | 29.08 Bn | 1.16 Mn | 83.34 Mn |
| 10 | Dyadic International | 18.44 Mn | 10.48 Mn | - | 5.64 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 5.64 Mn |
| Dec 31, 2025 | 192,339.00 |
| Sep 30, 2025 | 5.93 Mn |
| Jun 30, 2025 | 6.00 Mn |
| Mar 31, 2025 | 6.30 Mn |
| Dec 31, 2024 | 274,808.00 |
| Sep 30, 2024 | 5.85 Mn |
| Jun 30, 2024 | 5.83 Mn |
| Mar 31, 2024 | 5.91 Mn |
| Dec 31, 2023 | 297,859.00 |
| Sep 30, 2023 | 5.50 Mn |
| Jun 30, 2023 | 5.46 Mn |
| Mar 31, 2023 | 5.42 Mn |
| Dec 31, 2022 | 480,734.00 |
| Sep 30, 2022 | 5.28 Mn |
| Jun 30, 2022 | 5.50 Mn |
| Mar 31, 2022 | 5.43 Mn |
| Dec 31, 2021 | 459,702.00 |
| Sep 30, 2021 | 4.82 Mn |
| Jun 30, 2021 | 4.80 Mn |